Your session is about to expire
← Back to Search
RO7234292 (RG6042) for Huntington's Disease
Study Summary
This trial will study the long-term effects of RO7234292 on people who have completed other studies on Huntington's disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 236 Patients • NCT03842969Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What have been the most commonly reported side effects of RO7234292 (RG6042)?
"RO7234292 (RG6042) has received a score of 3 for safety. This is because Phase 3 trials have shown some efficacy and multiple rounds of data support the drug's safety."
How many different settings are included in this trial?
"Patients are being accepted at a number of locations, these include but are not limited to: Ottawa Hospital Research Institute in Ottawa, Ontario; CenExel Rocky Mountain Clinical Research, LLC in Englewood, Colorado; and University of British Columbia Hospital; Division of Neurology in Vancouver, British Columbia."
Are patients currently being accepted for this trial?
"Unfortunately, this particular clinical trial is not recruiting patients at the moment. Although the last update was on October 27th, 2022, the initial posting was on April 23rd, 2019. Having said that, there are 37 other trials that are presently looking for candidates."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger